01/06/2026
The world may feel heavy right now. And in women’s health, safety and equality, there is no shortage of challenges. The gaps remain serious, systemic, and unacceptable.
So it’s all the more important to recognise when progress happens.
For the first time in more than 30 years, new contraceptive options were added to the Pharmaceutical Benefits Scheme (PBS) in 2025, improving affordability for many women.
Medications such as:
• Yaz and Yasmin reduced from around $316 per year to $126.40, or $30.80 with a concession card.
• The NuvaRing reduced from over $270 per year to $31.60 per script.
• Long-acting contraceptives, including IUDs, became more accessible, with out-of-pocket costs reduced by up to $400.
• From January 2026, PBS scripts are capped at a maximum of $25.
In the past year, more than 303,000 women have accessed these lower-cost options.
This progress matters.
Cost is a well-documented barrier to accessing contraception, and reducing this barrier supports greater autonomy and choice.
At the same time, gaps in women’s healthcare remain, and continued advocacy is essential.
Recognising progress does not mean the work is done. But it does show that sustained advocacy and policy change can lead to meaningful improvements in access and equity.